Literature DB >> 6723764

Pharmacokinetic and pharmacodynamic modelling with pancuronium.

M A Evans, C A Shanks, K F Brown, E J Triggs.   

Abstract

The pharmacokinetics and pharmacodynamics of pancuronium were studied following intravenous infusion in eleven patients undergoing surgical anaesthesia. Measurement of the plasma concentrations (Cp) of the neuromuscular blocking agent ( NMBA ) and the concomitant intensities of paralysis allowed their simultaneous modelling. The pharmacokinetic parameters derived for pancuronium were in the range of previously reported values, except that the mean total systemic plasma clearance (0.79 +/- 0.28 ml X min-1 X kg-1) was reduced and the mean terminal phase half-life (169 min) was longer in these patients. Plasma concentration and % paralysis data were successfully fitted to a previously proposed pharmacodynamic model. This model assumes a separate effect compartment which exchanges drug directly with the central kinetic compartment (integrated effect model). The 'steady-state' Cp necessary to produce 50% paralysis ( ECpss (50] was estimated to be 0.21 +/- 0.08 micrograms X ml-1 (mechanical response) and 0.18 +/- 0.05 micrograms X ml-1 (EMG response). An analysis using the Hill equation of the Cp-response relationship, during and after the constant-rate infusion of pancuronium bromide, resulted in effective plasma concentrations for 50% paralysis ( ECp50 ) of 0.35 +/- 0.06 micrograms X ml-1 and 0.20 +/- 0.09 micrograms X ml-1, respectively, for mechanical twitch response. The corresponding values for EMG response were 0.32 +/- 0.06 micrograms X ml-1 and 0.17 +/- 0.06 micrograms X ml-1. Using this latter approach, the ECp50 estimated during onset of paralysis was significantly higher than that estimated during offset of paralysis (p less than 0.05); no such difference was apparent between this latter parameter and the ECpss (50) of the integrated effect model (p greater than 0.05). No significant differences were observed between any of the pharmacodynamic parameter estimates generated from the data obtained from the two methods of assessment of neuromuscular function (mechanical vs. EMG response) (p greater than 0.05).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6723764     DOI: 10.1007/BF00630293

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

2.  The dependence of pancuronium- and d-tubocurarine-induced neuromuscular blockades on alveolar concentrations of halothane and forane.

Authors:  R D Miller; W L Way; W M Dolan; W C Stevens; E I Eger
Journal:  Anesthesiology       Date:  1972-12       Impact factor: 7.892

3.  Effects of ageing on the pharmacokinetics of pancuronium.

Authors:  K McLeod; C J Hull; M J Watson
Journal:  Br J Anaesth       Date:  1979-05       Impact factor: 9.166

4.  Pharmacokinetic analysis on the disappearance of ethoxybenzamide from plasma. Statistical treatment of data of two compartmental model by a digital computer.

Authors:  H Nogami; M Hanano; S Awazu; H H Moon
Journal:  Chem Pharm Bull (Tokyo)       Date:  1969-10       Impact factor: 1.645

5.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man.

Authors:  J G Wagner
Journal:  J Theor Biol       Date:  1968-08       Impact factor: 2.691

6.  Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HC1 in healthy subjects: multiple-dose oral administration.

Authors:  H G Boxenbaum; K A Geitner; M L Jack; W R Dixon; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1977-02

Review 7.  The modelling of drug response.

Authors:  B Whiting; A W Kelman
Journal:  Clin Sci (Lond)       Date:  1980-11       Impact factor: 6.124

8.  Simultaneous pharmacokinetic and pharmacodynamic modeling.

Authors:  W A Colburn
Journal:  J Pharmacokinet Biopharm       Date:  1981-06

9.  Relationship between gallamine plasma concentration and neuromuscular paralysis in surgical patients.

Authors:  I M Ramzan; C A Shanks; E J Triggs
Journal:  J Clin Pharmacol       Date:  1983 May-Jun       Impact factor: 3.126

10.  Tubocurarine and pancuronium: a pharmacokinetic view.

Authors:  C A Shanks; A A Somogyi; M I Ramzan; E J Triggs
Journal:  Anaesth Intensive Care       Date:  1980-02       Impact factor: 1.669

View more
  3 in total

Review 1.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  Local epicardial inotropic drug delivery allows targeted pharmacologic intervention with preservation of myocardial loading conditions.

Authors:  Mark A Lovich; Abraham E Wei; Mikhail Y Maslov; Peter I Wu; Elazer R Edelman
Journal:  J Pharm Sci       Date:  2011-06-30       Impact factor: 3.534

3.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.